 |
|
|
| |
A Phase 3 Study Comparing Tenofovir Alafenamide to Tenofovir Disoproxil Fumarate in Patients
With HBeAg-Positive, Chronic Hepatitis B: Efficacy and Safety Results at Week 96
|
| |
| |
Reported by Jules Levin
EASL 2017 April 19-21 Amsterdam Netherlands
# FRI-153
Kosh Agarwal,1 Scott Fung,2 Wai Kay Seto,3 Young-Suk Lim,4 Edward Gane,5 Harry L.A. Janssen,6 Manoj Sharma,7 Wan-Long Chuang,8 Ho Bae,9 Ki Tae Yoon,10 John F. Flaherty,11 Audrey Lau,11 Anuj Gaggar,11 Vithika Suri,11 Andrea Cathcart,11 Lanjia Lin,11 G Mani Subramanian,11 Shalimar,12 Norihiro Furusyo,13 Maria Buti,14 Henry L.Y. Chan15
1King's College Hospital, London, UK; 2Toronto General Hospital, Toronto, Ontario, Canada; 3Queen Mary Hospital, Hong Kong; 4ASAN Medical Center, Seoul, South Korea; 5Auckland Clinical Studies, Auckland, New Zealand; 6Toronto Western Hospital, Toronto, and Erasmus MC, Rotterdam, the Netherlands; 7Institute of Liver & Biliary Sciences, New Delhi, India; 8Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan; 9Asian Pacific Liver Center, Los Angeles, California, USA; 10Pusan National University Yangsan Hospital, Yangsan-si, South Korea; 11Gilead Sciences, Inc., Foster City, California; 12All India Institute of Medical Sciences, New Delhi, India; 13Kyushu Medical Center, Fukuoka, Japan; 14Vall d'Hebron Hospital, Barcelona, Spain; 15The Chinese University of Hong Kong
|
| |
|
|
|
|
|
